HIF1A and central nervous system cancer: All these considerations contributed to elect HIF-1α not only as an early biomarker of responsiveness to TMZ [9], but also as a biomarker of CMA switch on/off in glioma, being crucial for glioma cell responsiveness to TMZ treatment.